You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas

 

Online download statistics by month:

Online download statistics by month: November 2020 to October 2024

AbstractFullPdf
Nov 2020340039
Dec 202011807
Jan 2021115017
Feb 2021192028
Mar 2021244049
Apr 2021186041
May 202149023
Jun 20210029
Jul 20210033
Aug 20210050
Sep 20210036
Oct 2021102040
Nov 2021138038
Dec 2021102033
Jan 2022172032
Feb 2022116038
Mar 2022108031
Apr 2022156033
May 202288024
Jun 2022134030
Jul 2022210032
Aug 2022174029
Sep 2022142029
Oct 202298019
Nov 2022112017
Dec 202284013
Jan 2023104016
Feb 202394010
Mar 20239606
Apr 202360013
May 202396012
Jun 2023104015
Jul 202392017
Aug 202370015
Sep 2023102017
Oct 20237009
Nov 202360012
Dec 20237806
Jan 20244605
Feb 20244204
Mar 20247006
Apr 20246804
May 20246607
Jun 20246709
Jul 20246605
Aug 202482019
Sep 202452017
Oct 202470018
Total483501032